Member Info for Prion25

I am currently invested in REDX and ETX which have both gone private .I held the the shares which were in an ISA unfortunately cannot be retained in the ISA but moved to a non ISA account .Your broker if you want to trade share after delisting then your broker can set up a matched bargain facility with J P Jenkins which specialises in companies that have gone private . I read that there may many AIM companies consideration leaving the UK to seek more value with Nasdaq Great news for inherited hearing loss children perhaps GDR pharmacogenomics can develop a test for this rogue gene

O/T

seen on another BB clutching at straws I know , this and long Covid are opportunities which you would think Synairgen team would be exploiting

https://www.gov.uk/government/news/new-five-year-plan-to-combat-antimicrobial-resistance

https://www.grandviewresearch.com/industry-analysis/antibiotic-resistance-market

Https://jpjenkins.com/wp-content/uploads/dlm_uploads/2023/10/List-of-JPJ-Brokers.pdf

from jp jenkins website HL "sell only"

Thanks moniman - Got it .

HL said when I contacted them on the 3rd of May said that they would let me know the matched bargain facility with JP Jenkins becomes available I feel that they are not quite up to speed on this atm I also mention ETX another delisted share I am invested in . J P Jenkins are alert and ready to go when I emailed them recently

Great post Lionel1

Musk visit to China signals the Chinese are desperate to resume trading with West to reinvigorate their economy?

Is AS ‘s name on the patents ? Good luck Al and thanks for your fantastic scientific contributions

Remarkable news. How many small pharma companies get fast track opportunities like this in the US.

Stephen Diggle is the Founder and CEO of Vulpes Investment Management, a family office-backed investment manager. Let me provide you with more details about his background:

Stephen Diggle has been working in finance since 1986.

He spent 15 years working at international investment banks in London, Sydney, and Hong Kong.

He was one of the two founders of Artradis Fund Management, a Singapore-based hedge fund company that launched in 2002 with US$4 million and peaked at nearly US$5 billion late in 2008.

Artradis was multi-award-winning and, for some time, the largest and most successful hedge fund in Asia, making US$2.7 billion for investors between 2002 and 2009, especially during the financial crisis of 2008.

Following the success of Artradis, Stephen founded Vulpes Investment Management in 2011. Vulpes is a diversified family office-led investment company that runs a diverse portfolio of assets.

Vulpes has been an early investor in companies such as Scancell and Oxford Biomedica, providing capital at critical times to keep these companies afloat.

Stephen holds a Master’s degree from the University of Oxford in Philosophy, Politics, and Economics1.

Stephen Diggle’s expertise in finance and his passion for finding undervalued biotech firms make him a significant player in the investment world.

vulpesinvest.com

bing.com

4

pilgrimammunition.com

5

pitchbook.com

What other companies has Vulpes invested in?

Tell me more about Artradis Fund Management.

How can I contact Stephen Diggle?

Chats

Plug-ins

Copilot GPTs

Copilot

Copilot

Designer

Designer

Vacation planner

Vacation planner

Cooking assistant

Cooking assistant

Fitness trainer

Fitness trainer

Recents

Stephen Diggle: Vulpes CEO and Investment Expert

Write about flavors and tastes or a favorite spice of yours

Yesterday

UK Companies Developing Sepsis Diagnostic Tests

2 days ago

Response stopped

New topic

Derived from my copilot AI search

Yes, Alma Maritime Group is indeed using Ceres’ Solid Oxide Fuel Cell (SOFC) technology in its new vessel. Alma Maritime Group and Ceres have announced a collaboration to demonstrate an 80kW LNG fuelled system in 2024

Ceres will provide solid oxide fuel cell stacks for the development and validation of the power system. Meanwhile, Alma will develop and build the 80kW system that will be tested during 2024 in Stord, Norway, before being transferred to a vessel for further testing

The partnership aims to combine Ceres’ highly efficient technology with Alma’s marine systems development capabilities and market access. This collaboration is expected to drive the transition to a greener future for shipping

ALSO

Alma Maritime Group, in collaboration with Hydrogenious LOHC Technologies and Hydrogenious LOHC Maritime, has announced a joint development agreement to engineer a fully integrated LOHC-SOFC (Liquid Organic Hydrogen Carrier-Solid Oxide Fuel Cell) power system12. This is a first-of-its-kind system for maritime use.

The project, supported by Enova, focuses on a 100-kilowatt pilot powertrain to be demonstrated on board the Østensjø Rederi operated offshore supply vessel Edda Ferd2. The innovation combines hydrogen release from the LOHC with direct conversion into power by an adjacent SOFC unit to the benefit of high efficiency. The key to this lies in using the SOFC device’s excess heat to meet the LOHC release unit’s heat demand.

Hydrogenious’ LOHC solution provides a safe and easy method for handling hydrogen as a fuel, facilitating the decarbonisation of the maritime industry. The agreements also open up for hydrogen-powered vessels on megawatt-scale later.

This partnership leverages synergies between Alma’s SOFC solution and Hydrogenious LOHC technology, taking the next milestone in pioneering the use of hydrogen as a safe and efficient zero emission fuel to ships

@ CJ39

I think you are correct Stalica if you read their research there is a great unmet need for neurological drugs for conditions such as ASD Trials of recently tested drugs have failed to meet their endpoints with “The one size fits all approach “and a stratification approach is required for investigation with novel drugs This is where I think Stalica are desperate to get Evgen but on cheap !

Info@jpjenkins.com

anybody still confused like me about Match Bargain Facility dealing contact the above are very helpful .H&L staff when I contacted them seem to a bit vague about the process but JP Jenkins reassured me they will be processing delisted REDX and ETX from H& L GLA

Bryan Garnier cuts Ceres Power price target to 190 (220) pence - 'neutral'

@moniman @mthomas

Thanks for your info much appreciated

Berenberg cuts Ceres Power price target to 650 (800) pence - 'buy'

-Goldman Sachs cuts Ceres Power price target to 230 (270) pence - 'buy'

FWIW last opportunity to vote today .I had an email from Hargreaves & L to vote yesterday .Also they told me that my Redx shares they would be remove the shares from my ISA to my non ISA trading account at the time of delisting .It's not clear what happens then will I be able to sell or not or would it be better to sell before the 19th within the ISA preserving the cash tax benefit .Then at what price ! Hunt said invest in ISA British Companies .He didn't mention you might be mugged off absolute day light robbery never again got Etx to contend with next Appreciate comment from other share holders GLA

Https://www.propharmagroup.com/thought-leadership/fda-expedited-approvals

More on fast tracking

Should be * non invasive “

@B2H

"I could understand this patient, who must be due a scan shortly, must be feeling great to be alive, but possibly nonplussed to find the reduction in his tumour diameters were from 65% to only 74%."

From my research in general terms the tumour will probably will appear in the next scan but after prolonged chemo if it has not grown further then with 74% or more shrinkage might be considered non evasive and will not spread .Some tumours disappear spontaneously after infection but this phenomenon is not understood